Wellness in women after 40 years of age: The role of sex hormones and pheromones

Cutler, Winnifred B.; Genovese-Stone, Elizabeth

doi:10.1016/s0011-5029(98)90016-5

Cited by 12 publications

(6 citation statements)

References 264 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reports of deterioration of sexual function after hysterectomy is estimated to be between 13% and 37%, which may be through one or more mechanisms [153][154][155][156][157][158]. Quality of sexual life after hysterectomy may be influenced by several situations resulting in conflicting suggestions [159][160][161][162][163][164][165]. Many of the studies exploring sexuality after hysterectomy have methodological flaws, including vague measures of sexual satisfaction and potential for recall bias [166].…”

Section: Pelvic Surgerymentioning

confidence: 99%

“…Loss of a physiologic level of testosterone in women after hysterectomy can decrease quality of life in terms of libido, sexual pleasure, and sense of well-being. An analysis by Cutler and Genovese-Stone correlated the impact of hormonal deficit on sexuality and overall quality of life in hysterectomized women [162]. In the U.S. more than half a million women per year undergo hysterectomy as treatment for chronic benign gynecologic conditions [167], a rate five times higher than that of the European countries.…”

Section: Pelvic Surgerymentioning

confidence: 99%

“…Estrogen, progesterone, and androgen levels all tend to be altered by hysterectomy. Furthermore, all these sex hormones affect physiologic systems including the cardiovascular system, bone metabolism, cognitive function, sexual response, and sexual attractiveness [162].…”

Section: Pelvic Surgerymentioning

confidence: 99%

See 2 more Smart Citations

Clinical Biologic Pathophysiologies of Women's Sexual Dysfunction

Nappi

Salonia

Traish

et al. 2005

The Journal of Sexual Medicine

117

107

View full text Add to dashboard Cite

Introduction Data concerning the biologic pathophysiology of desire, arousal, and orgasm in women are limited. Aim To gain knowledge of biologic paThophysiology of female sexual function. Methods To provide state-of-the-art knowledge concerning female sexual dysfunction, representing the opinions of seven experts from five countries developed in a consensus process over a 2-year period. Main Outcome Measure An International Consultation in alliance with key urological and sexual medicine societies convened over 200 multidisciplinary specialists from 60 countries into 17 consultation committees. The aims, goals and intentions of each committee were defined. Expert opinion was based on grading of evidence-based medical literature, extensive internal committee dialogue, open presentation, and debate. Results Three critical physiologic requirements, including intact sex steroids, autonomic/somatic nerves, and arterial inflow/perfusion pressure to women's genital organs play fundamental roles in maintaining women's sexual function. Despite this, there are nominal data supporting a direct pathophysiologic involvement of abnormal sex steroid values, and/or damage/injury to neurologic and/or blood flow integrity in women with problems in sexual desire, arousal, and/or orgasm. This summary details the available literature concerning hormonal, neurologic, and vascular organic pathophysiologies of women's sexual dysfunctions. Conclusions Additional research on clinical pathophysiologies in women's sexual dysfunction is needed. This chapter encompasses data presented at the 2nd International Consultation on Sexual Medicine in Paris, France, June 28–July 1, 2003.

show abstract

Section: Pelvic Surgerymentioning

confidence: 99%

Section: Pelvic Surgerymentioning

confidence: 99%

See 1 more Smart Citation

Clinical Biologic Pathophysiologies of Women's Sexual Dysfunction

Nappi

Salonia

Traish

et al. 2005

The Journal of Sexual Medicine

117

107

View full text Add to dashboard Cite

show abstract

“…Mice with increased oocyte reserves do much better with aging [Perez et al, 2007]. Epidemiologic studies support the role of ovarian aging in women's well being [Cutler and Genovese-Stone, 1998], and cardiovascular disease, osteoporosis, and mortality are accelerated with premature ovarian aging [Senöz et al, 1996;Allen et al, 2007].…”

Section: Discussionmentioning

confidence: 99%

Recent Developments in Identifying Genetic Determinants of Premature Ovarian Failure

Skillern

Rajkovic

2008

Sex Dev

View full text Add to dashboard Cite

Premature ovarian failure (POF) is defined as cessation of menstruation and associated elevation of gonadotropin levels (FSH >40 IU/l) as a result of decreased ovarian function prior to the age of 40. An estimated 1% of the population is affected before age 40, with 0.1% affected prior to age 30. Although the causes for POF are many, the majority of POF cases have idiopathic etiologies. In an effort to investigate potential mechanisms of the disease, genetic determinants of POF have received particular attention in recent years. Transgenic mouse models have been instrumental in the discovery of novel genetic determinants of gonadal development and failure and have informed research identifying mutations in women with POF. Here, we review recent developments in identifying genetic determinants of POF.

show abstract

“…Hormones are used to treat a variety of problems and disorders such as cancers (prostate, ovaries and breast), [1][2][3] aging, [4,5] sex reassignment, [6] intersex conditions such as Klinefelter's and Turner syndrome, [7,8] and hormonal deficiencies, for example in growth deficiencies and hypothyroidism. [9,10] The mechanisms of therapeutic effects of hormones are both direct and indirect, in that hormones can either affect directly on their target organs as an exogenous source or regulate the secretion of other endogenous hormones based on positive or negative feedbacks.…”

Section: Introductionmentioning

confidence: 99%

Design, preparation and characterization of novel poly-lactic-co-glycolic acid-hyaluronic acid implants containing triptorelin acetate

Dorkoosh¹,

Omid²,

Toopchi³

et al. 2014

Asian J Pharm

View full text Add to dashboard Cite

H ormones and their derivatives are widely used to treat different types of diseases such as prostate cancer which is treated by agonists of gonadotropin-releasing hormone. Triptoreline salts are the first therapeutics of this group launched into the market in the form of microparticles (microspheres). Implants, as one of attractive injectable dosage forms, have many advantages over multi-particulate systems. Some of these advantages are dose adjustability, drug absorption improvement, constant release profile, etc. In this research, a new composite of poly-lactic-co-glycolic acid and hyaluronic acid was designed and prepared in the form of implants containing triptorelin acetate for administration as an injection under the skin (subcutaneously) in arm or thigh area. The manufactured implants characterized by Fourier transform infrared spectroscopy, thermas gravimetric analysis, X-ray diffraction and scanning electron microscopy to assess different aspects of structure and morphology. The drug release profile was assessed by high performance liquid chromatography. These characterizations confirmed that the newly designed drug delivery has a good stability during manufacturing process. The release pattern of the implant was also studied and revealed that the release of the model drug follows a zero-order and erosion mechanism. The compatibility between the components of the newly designed implants and the release profile of the delivery system make it a promising device for drug delivery.

show abstract

Wellness in women after 40 years of age: The role of sex hormones and pheromones

Cited by 12 publications

References 264 publications

Clinical Biologic Pathophysiologies of Women's Sexual Dysfunction

Clinical Biologic Pathophysiologies of Women's Sexual Dysfunction

Recent Developments in Identifying Genetic Determinants of Premature Ovarian Failure

Design, preparation and characterization of novel poly-lactic-co-glycolic acid-hyaluronic acid implants containing triptorelin acetate

Contact Info

Product

Resources

About